Brusselle, GuyPrice, DavidGruffydd-Jones, KevinMiravitlles, MarcKeininger, Dorothy LStewart, RebeccaBaldwin, MichaelJones, Rupert C2015-12-032015-12-032015Brusselle, G, Price, D, Gruffydd-Jones, K, Miravitlles, M, Keininger, D L, Stewart, R, Baldwin, M & Jones, R C 2015, 'The inevitable drift to triple therapy in COPD : an analysis of prescribing pathways in the UK', International journal of chronic obstructive pulmonary disease , vol. 10, no. 1, pp. 2207-2217. https://doi.org/10.2147/COPD.S916941176-9106http://hdl.handle.net/2164/5280Acknowledgments The analyses reported in this study were funded by Novartis Pharma AG (Basel, Switzerland) and were conducted by Research in Real-Life Ltd (Cambridge, UK), an independent company. The authors also thank David Bergin, Danielle Corbett, and Vivek Khanna (professional medical writers; Novartis) for assistance in the preparation of this paper. Writing support was funded by Novartis Pharma AG.11644890engchronic obstructive pulmonary diseaseGOLD guidelinesobservational studyprescribing patternsprimary careR MedicineRJournal article10.2147/COPD.S91694101